Daniela Verani, MD
Family Medicine · Londonderry, NHNPI 1255431532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 57.7% of the total. Reporting peaked in 2021 at $365 and has fallen 83.6% since, to $60 in 2024.
Across 62 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$751
- Kowa Pharmaceuticals America, Inc.$155
- Amarin Pharma, Inc.$146
- Johnson & Johnson$115
- Esperion Therapeutics, Inc.$81
- Lilly USA, LLC$20
- plus $34 from 2 others
What the payments were for
- Food & beverage$1,296100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $751 |
| Kowa Pharmaceuticals America, Inc. | 8 | $155 |
| Amarin Pharma, Inc. | 7 | $146 |
| Johnson & Johnson | 6 | $115 |
| Esperion Therapeutics, Inc. | 4 | $81 |
| Lilly USA, LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$1,302 in reported general payments places this provider in the 85th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 22 | $1,885 |
| Olmesartan Medoxomil | 77 | $1,473 |
| Atorvastatin Calcium | 100 | $985 |
| Metoprolol Succinate | 49 | $801 |
| Rosuvastatin Calcium | 53 | $778 |
| Ezetimibe | 23 | $775 |
| Lisinopril | 89 | $575 |
| Levothyroxine Sodium | 59 | $575 |
| Simvastatin | 48 | $414 |
| Amlodipine Besylate | 65 | $354 |
| Pravastatin Sodium | 30 | $282 |
| Allopurinol | 24 | $213 |
| Trazodone Hcl | 43 | $185 |
| Famotidine | 11 | $183 |
| Hydrochlorothiazide | 35 | $80 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Londonderry
- Christine HandLondonderry$3K
- Daniel WaszkowskiLondonderry$2K
- Mark BallentynePortsmouth$135K
- M LauterPortsmouth$21K
- Brian SponsellerNorth Conway$15K
- Cecilia Vicuna KeadyCharlestown$13K
- Keenan Al-HojerryPortsmouth$11K
- Peter LoeserConcord$10K
- Robyn StewartDerry$8K
- Robert KellyExeter$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.